Xianjun Yu

ORCID: 0000-0002-6697-7143 · 4 papers in corpus
nonrandomized-trial 2025
A phase 1b/2 study of first-line anti-PD-L1/ TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitabine for advanced pancreatic ductal adenocarcinoma.
Signal transduction and targeted therapy ·doi:10.1038/s41392-025-02530-2

Nab-paclitaxel plus gemcitabine (AG) is the standard first-line chemotherapy for advanced or metastatic pancreatic ductal adenocarcinoma and has limited efficacy. This phase 1b/2 study aimed to evaluate SHR-1701 (an anti-PD-L1/TGF-βRII fusi…

other 2022
Carbohydrate antigen 125 supplements carbohydrate antigen 19-9 for the prediction of invasive intraductal papillary mucinous neoplasms of the pancreas
World journal of surgical oncology ·doi:10.1186/s12957-022-02720-0

BACKGROUND: Intraductal papillary mucinous neoplasms (IPMNs) are characterized by their abundant mucin production and malignant potential. IPMNs of the pancreas are mainly managed according to their radiographic indications, but this approa…

2020
Pancréatectomie totale laparoscopique avec conservation de la rate pour TIPMP (avec vidéo)
·doi:10.1016/j.jchirv.2020.05.006
observational 2015
Preoperative serum CA125 levels predict the prognosis in hyperbilirubinemia patients with resectable pancreatic ductal adenocarcinoma
Medicine ·doi:10.1097/md.0000000000000751

Serum carbohydrate antigen 19-9 (CA19-9) is widely used to predict the prognosis for pancreatic ductal adenocarcinoma (PDAC). However, hyperbilirubinemia and the CA19-9 nonsecretor phenotype restrict the usage of serum CA19-9 alone. The goa…